Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

NKTX
Nkarta, Inc. Common Stock
stock NASDAQ

Market Open
Oct 2, 2026 10:34:21 AM EDT
2.59USD+0.977%(+0.03)51,110
2.58Bid   2.59Ask   0.01Spread
Pre-market
Sep 28, 2026 9:22:30 AM EDT
2.78USD+8.594%(+0.22)0
After-hours
Oct 1, 2026 4:30:30 PM EDT
2.53USD-1.172%(-0.03)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 6, 2022
08:37AM EST  William Blair Initiates Coverage On Nkarta with Outperform Rating   Benzinga
Dec 16, 2021
08:09AM EST  Nkarta Reports Receives US FDA Orphan Drug Designation For NKX101 For Treatments Of Patients With Acute Myeloid Leukemia   Benzinga
08:02AM EST  Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NKX101 for treatment of acute myeloid leukemia (AML).   GlobeNewswire Inc
Dec 13, 2021
04:04PM EST  Nkarta Presents NKX019 Trial In Progress Poster At ASH 2021 Meeting   Benzinga
04:02PM EST  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today presented a trial in progress poster on NKX019 for the treatment of relapsed and refractory B-cell malignancies at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH).   GlobeNewswire Inc
Nov 18, 2021
09:24AM EST  SMBC Nikko Initiates Coverage On Nkarta with Outperform Rating, Announces Price Target of $50   Benzinga
Nov 12, 2021
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:18AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:15AM EST  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs.   GlobeNewswire Inc
Nov 10, 2021
04:06PM EST  Nkarta Q3 EPS $(0.68) Up From $(6.08) YoY   Benzinga
04:01PM EST  -- Initial data expected in 1H 2022 from Phase 1 clinical trial of NKX101 in AML and MDS -- Successful dosing of NKX019 in patients with B cell malignancies; initial Phase 1 clinical trial data expected in 2022   GlobeNewswire Inc
Nov 4, 2021
08:04AM EDT  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:   GlobeNewswire Inc
Oct 28, 2021
10:01AM EDT  MaxCyte Reports Strategic Platform License With Nkarta to Advance Natural Killer Cell Therapy Programs   Benzinga
Oct 8, 2021
08:11AM EDT  Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022   Benzinga
Oct 7, 2021
04:01PM EDT  Nkarta Announces Updates To NKX019 and NKX101 Clinical Development Programs   Benzinga
04:01PM EDT  -- First patients dosed in Phase 1 clinical trial evaluating NKX019 in CD19+ advanced B cell malignancies -- Initial data from the NKX019 clinical trial expected in 2022 -- Initial data from Phase 1 clinical trial evaluating NKX101 in AML and MDS expected in 1H 2022   GlobeNewswire Inc
Oct 1, 2021
08:26AM EDT  Nkarta To Present Preclinical Data From Engineered NK Cell Platform At SITC 36th Annual Meeting Nov. 10-14   Benzinga
08:08AM EDT  -- Data support potential clinical applications of CRISPR/Cas9 genome engineering, CD70 chimeric antigen receptor (CAR) targeting, and donor selection algorithms in next generation NK cell development programs -- Update also highlights novel methods for scaling the expansion of engineered NK cells to potentially supply a life cycles worth of commercial product from a single donor   GlobeNewswire Inc
Sep 14, 2021
08:32AM EDT  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:   GlobeNewswire Inc
Aug 12, 2021
05:28PM EDT  Nkarta Files For Mixed-Securities Shelf Offering Of Up To $500M   Benzinga
04:43PM EDT  Nkarta Q2 EPS $(0.66) Misses $(0.61) Estimate   Benzinga
04:02PM EDT  -- Initial data from NKX101 clinical trial expected by end of 2021 -- NKX019 patient dosing expected to start in 2H 2021 -- Collaboration with CRISPR Therapeutics to develop gene-edited cell therapies -- New lease for commercial manufacturing center / headquarters to support rapid innovation and scaled production of NK cell therapies   GlobeNewswire Inc
Jul 16, 2021
10:15AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021   Benzinga
05:05AM EDT  Oppenheimer Initiates Coverage On Nkarta with Outperform Rating, Announces Price Target of $75   Benzinga
Jul 15, 2021
04:58PM EDT  Hearing Nkarta Initiated With Outperform Rating At Oppenheimer   Benzinga
Jul 14, 2021
09:07AM EDT  Nkarta Unveils Plans For New San Francisco HQ, Manufacturing Site   Benzinga
07:13AM EDT  Nkarta 8-K Shows Co. Entered Into Triple Net Lease Between Co., HCP BTC For Lease Of Existing Office Building In San Francisco, California   Benzinga
07:00AM EDT  Nkarta Establishes New Combined NK Cell Therapy Manufacturing   GlobeNewswire Inc
Jun 16, 2021
07:00AM EDT  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:   GlobeNewswire Inc
Jun 14, 2021
07:01AM EDT  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Chief Executive Officer Paul Hastings has been elected as the Chair of the Biotechnology Innovation Organization (BIO) Board of Directors for the 2021-2022 term.   GlobeNewswire Inc
May 25, 2021
07:30AM EDT  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:   GlobeNewswire Inc
May 13, 2021
04:26PM EDT  Nkarta Q1 EPS $(0.59) Up From $(5.41) YoY   Benzinga
04:02PM EDT  Nkarta Reports First Quarter 2021 Financial Results and Business   GlobeNewswire Inc
May 7, 2021
11:40AM EDT  Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer   Benzinga
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
04:01PM EDT  -Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities-   GlobeNewswire Inc
Apr 28, 2021
08:05AM EDT  Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies   Benzinga
08:02AM EDT  -- NKX019 to be Nkartas second CAR NK pipeline program to enter clinical trial   GlobeNewswire Inc
Apr 6, 2021
08:05AM EDT  The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout   Benzinga
Mar 25, 2021
04:05PM EDT  Nkarta Q4 EPS $(0.55), Up From $(6.62) YoY   Benzinga
04:03PM EDT  Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results   GlobeNewswire Inc
Feb 17, 2021
04:03PM EST  Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:   GlobeNewswire Inc
Jan 5, 2021
10:47PM EST  The lockup period of Nkarta Inc. (NKTX) expires tomorrow, i.e. on Jan 6.   RTTNews
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Nov 12, 2020
04:08PM EST  Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101   Benzinga
04:06PM EST  Nkarta Reports Q3 EPS $(0.44); Sees Current Cash, Cash Equivalents At Dec. 31, 2020 $300M-$310M   Benzinga
04:03PM EST  Nkarta Reports Third Quarter 2020 Financial Results   GlobeNewswire Inc
04:02PM EST  Nkarta Announces Treatment of First Patient in First-in-Human   GlobeNewswire Inc
Nov 9, 2020
08:13AM EST  Nkarta Announces Presentation Of Preclincal Data On NKX019 At Annual Meeting Of Society For Immunotherapy Of Cancer   Benzinga
08:02AM EST  Nkarta Announces Presentation of Preclinical Data on NKX019,   GlobeNewswire Inc
Oct 12, 2020
03:30PM EDT  Q3 The Busiest Since 2014 For IPOs, Led By Unicorns, SPACs   Benzinga
Oct 5, 2020
04:03PM EDT  Nkarta Announces Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer; Alicia J. Hager, J.D., Ph.D. to Join as Chief Legal Officer   Benzinga
04:03PM EDT  Nkarta Announces That Nadir Mahmood Was Named To Expanded Role As CFO & Chief Business Officer   Benzinga
04:02PM EDT  Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business OfficerAlicia J. Hager, J.D., Ph.D.to Joinas Chief Legal Officer   GlobeNewswire Inc
Sep 29, 2020
08:02AM EDT  Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will participate at the following virtual investor conference:   GlobeNewswire Inc
Aug 20, 2020
04:05PM EDT  Nkarta Q3 EPS $(30.06) Down From $(3.39) YoY   Benzinga
04:02PM EDT  Nkarta Reports Second Quarter 2020 Financial Results   GlobeNewswire Inc
Aug 6, 2020
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
Aug 4, 2020
09:35AM EDT  Benzinga's Top Upgrades, Downgrades For August 4, 2020   Benzinga
08:38AM EDT  Stifel Initiates Coverage On Nkarta with Buy Rating, Announces Price Target of $41   Benzinga
06:43AM EDT  Cowen & Co. Initiates Coverage On Nkarta with Outperform Rating   Benzinga
05:53AM EDT  Mizuho Initiates Coverage On Nkarta with Buy Rating, Announces Price Target of $34   Benzinga
Jul 23, 2020
01:49PM EDT  New Enterprise Associated 15 Reports 9.5% Stake In Nkarta Inc In 13D   Benzinga
Jul 18, 2020
04:22PM EDT  Notable Insider Buys: Bed Bath & Beyond, Poseida Therapeutics And More   Benzinga
Jul 16, 2020
04:38PM EDT  Novo Holdings Reports 8.59% Active Stake In Nkarta   Benzinga
Jul 15, 2020
05:39AM EDT  Biopharmaceutical Company Nkarta Raises $290M In IPO   Benzinga
Jul 14, 2020
04:27PM EDT  Nkarta Reports Closing Of IPO Of 16.1 Mln Shares   RTTNews
04:15PM EDT  Nkarta Announces Closing of Upsized Initial Public Offering and   GlobeNewswire Inc
11:45AM EDT  Nkarta 13G Filing From Hedge Fund Deerfield Mgmt. Shows 7.95% Stake In Co.   Benzinga
05:11AM EDT  80 Biggest Movers From Yesterday   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC